DDInter1570 DDInter228
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease.
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Ranolazine {u} (Compound) resembles {v} (Compound) Eprazinone
Eprazinone {u} (Compound) resembles {v} (Compound) Bepridil
Bepridil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Ranolazine {u} (Compound) resembles {v} (Compound) Eprazinone
Eprazinone {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Brentuximab vedotin
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nefazodone
Nefazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
DENND2D {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Ranolazine {u} (Compound) upregulates {v} (Gene) HIST2H2BE
HIST2H2BE {u} (Gene) is upregulated by {v} (Compound) Teniposide
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Ranolazine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Ranolazine (Compound) resembles Eprazinone (Compound) and Eprazinone (Compound) resembles Bepridil (Compound) and Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Ranolazine (Compound) resembles Eprazinone (Compound) and Eprazinone (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Brentuximab vedotin
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound) and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Ranolazine (Compound) upregulates DENND2D (Gene) and DENND2D (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Ranolazine (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is upregulated by Teniposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin